Results 111 to 120 of about 408 (149)
Some of the next articles are maybe not open access.
Facts and Hopes: Immunocytokines for Cancer Immunotherapy
Clinical Cancer Research, 2023Abstract The clinical development of cytokines as cancer therapeutics has been limited due to significant toxicities generally observed with systemic administration. This narrow therapeutic window, together with relatively modest efficacy, has made natural cytokines unattractive drug candidates.
Aliyah Pabani, Justin F. Gainor
openaire +2 more sources
Immunocytokines and Cytokine Neutralization for Cancer Immunotherapy
Trends in CancerDespite deep and growing knowledge of cytokine functions, immunotherapies based on the control of these molecules have minimally impacted cancer patient management because of limited efficacy and narrow therapeutic windows. Opportunities to enhance efficacy and mitigate side effects arise from local delivery and targeting antitumor cytokines to tumor ...
Ana Martínez-Riaño +2 more
exaly +3 more sources
[Immunotoxins and immunocytokines].
Medecine sciences : M/S, 2020Cytokines and biological toxins represent two potent classes of biomolecules that have long been explored for their potential as therapeutics. Considerable side effects and poor pharmacokinetics frequently observed with both have limited their broad application.
Alicia, Contet +3 more
openaire +1 more source
Immunocytokines: amplification of anti-cancer immunity
Cancer Immunology, Immunotherapy, 2003Many cancers elicit an anti-tumor immune response, which is nevertheless unable to protect the patient. One approach to boost anti-tumor immunity is to target immunostimulatory cytokines to the tumor. Such targeting can be achieved by generating chimeric proteins (immunocytokines) in which the cytokine in question is fused to the C-terminus of a tumor ...
Craig B, Davis, Stephen D, Gillies
openaire +2 more sources
Immunocytokines for Cancer Immunotherapy
2004Immunologic approaches to cancer therapy rely on two distinct capabilities of the immune system: targeting the tumor microenvironment by recognizing molecules expressed to a greater extent on tumor cells than normal cells and generating immune responses that can kill tumor cells (1,2).
Paul M. Sondel, Steven D. Gillies
openaire +1 more source
, 2023 IL-12 is a potent cytokine for cancer immunotherapy. However, its systemic delivery as a recombinant protein has shown unacceptable toxicity in early clinical trials, mostly related to the secondary increase in IFN- levels in circulation. In the last two
Di-Trani, C.A. (Claudia Augusta) +2 more
exaly +1 more source
Tripokin:
AbstractAntibodies that target the tumor microenvironment can be used to deliver pro‐inflammatory payloads, such as cytokines. Cytokines are small proteins able to modulate the activity of the immune system, and antibody–cytokine fusion proteins have been tested in preclinical and clinical settings.
Prodi, Eleonora +13 more
openaire +2 more sources
Preclinical and clinical development of immunocytokines.
Current opinion in investigational drugs (London, England : 2000), 2003Advances in preclinical and clinical development have demonstrated that monoclonal antibodies and immuno-activating cytokines have a beneficial role in certain clinical oncology settings. Genetic engineering has now been used to create 'immunocytokines (ICs)'.
Paul M, Sondel +4 more
openaire +1 more source